SCHEMBL18003207

SCHEMBL18003207

COC(=O)c1cccc(-c2nc3ccc(F)cc3o2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.62
▸ RAB9A P51151 5/20 0.57
▸ NPC1 O15118 4/20 0.57
▸ MAPT P10636 4/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ NFKB2 Q00653 1/20 0.57
▸ RELA Q04206 1/20 0.57
▸ ATM Q13315 1/20 0.57
▸ UTRN P46939 1/20 0.52
▸ HDAC6 Q9UBN7 4/20 0.51
▸ CEPT1 Q9Y6K0 1/20 0.49
▸ HDAC3 O15379 2/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC1 Q13547 2/20 0.48
▸ HDAC7 Q8WUI4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399885 0.91 HSPD1 (0.56) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL20898075 0.91 MAPT (0.60) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL4878083 0.87 MAPT (0.76) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL1675545 0.85 MAOA (0.55) GPR119RAB9ANPC1MAPTUTRN
SCHEMBL31247990 0.85 KDM4E (0.74) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL28605620 0.85 KDM4E (0.74) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL1675528 0.84 HDAC6 (0.51) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL20897629 0.84 MAPT (0.71) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL5642041 0.83 MAPT (0.64) GPR119RAB9ANPC1MAPTKDM4E
SCHEMBL144958 0.81 MAPT (0.71) GPR119RAB9ANPC1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 GPR119 27/4885RAB9A 4775/4885NPC1 1062/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 GPR119 27/4885RAB9A 4775/4885NPC1 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback